Jan B. Vermorken

Definitions for Response and Progression in Ovarian Cancer Clinical Trials Incorporating RECIST 1.1 and CA 125 Agreed by the Gynecological Cancer Intergroup (GCIG)

Gordon John Sampson Rustin, Ignace Vergote, Elizabeth A. Eisenhauer et al. · International Journal of Gynecological Cancer · 2011 · 619 citations

Medicine, Gynecology, Oncology +17

Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial

Jan B. Vermorken, A.M.E. Claessen, Harm van Tinteren et al. · The Lancet · 1999 · 503 citations · Full text

Medicine, Immunology, Oncology +10

2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004)

Andreas du Bois, Michael Quinn, Tate Thigpen et al. · Annals of Oncology · 2005 · 466 citations

Medicine, Gynecology, Oncology +17

Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial

Jan B. Vermorken, Jan Stöhlmacher-Williams, Lisa Licitra et al. · The Lancet Oncology · 2013 · 433 citations · Full text

Medicine, Oncology, Chemotherapy +10

Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial

Jean-Pascal H. Machiels, Robert I. Haddad, Jérôme Fayette et al. · The Lancet Oncology · 2015 · 392 citations

Medicine, Oncology, Chemotherapy +12